FDA Approves Pfizer and Arvinas' Breast Cancer Drug Veppanu

The U.S. Food and Drug Administration (FDA) has approved Veppanu, a breast cancer drug jointly developed by Pfizer and Arvinas. This approval offers a new treatment option for a specific type of breast cancer. Veppanu stands out as a drug designed for use in patients with metastatic breast cancer. The FDA's decision is based on data from clinical trials evaluating the drug's efficacy and safety. The collaboration between Pfizer and Arvinas is seen as a significant step in developing such innovative treatments. The approval is considered a positive financial development for both companies. This is not investment advice.

📊 PFE — Piyasa Yorumu

▲ up · 60%

The FDA approval can be considered a positive short-term catalyst for PFE. Technical indicators present a neutral-to-positive picture; the RSI at 53 is neither overbought nor oversold, while the MACD is approaching its signal line and could give a bullish crossover signal. The price is trading above the 20- and 50-day moving averages, supporting short-term momentum. However, the approval news may already be largely priced in, posing a risk of limited upside. Therefore, while the direction is upward, the confidence level is moderate.

RSI 14

53.6

MACD

-0.00

24h Δ

0.23%

📊 ABBV — Piyasa Yorumu

▼ down · 60%

ABBV stock fell 1.2% in the last session, with the RSI at 43, indicating a weak zone. The MACD line is below the signal line and negative, suggesting weak short-term momentum. The price is trading below both the 20-day and 50-day moving averages, which paints a negative technical outlook. News that ABBV, although not a direct competitor, could increase competition in the breast cancer space may pressure the stock. The downtrend is likely to continue in the short term.

RSI 14

43.1

MACD

-0.48

24h Δ

-1.20%

Canlı Grafikler